The orphan drug act: Provisions and considerations

Drug Information Journal

Volumn 34, Issue 1, 2000, Pages 295-300

  Reider, Carson R ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Drug development; Orphan Drug Act; Rare diseases

Indexed keywords

ORPHAN DRUG;

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; UNITED STATES;

EID: 0034086889     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150003400137     Document Type: Article

References (21)

1. Meyers AS. The US Orphan Drug Act: Should the law cover higher profitable drugs? World Pharmaceut. Standards Rev. 1991;1:24-25.
2. Brandissou S, Yagoubi N, Hasselot N. Orphan Drugs: a problem of public health and an economic stake. Therapie. 1996;51:647-653.
3. Shulman SR, Bienz-Tadmor B, Seo PS et al. Implementation of the Orphan Drug Act: 1998-1991. Food Drug Law J. 1992;47(4):363-403.
4. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expnaded surveillance case definitions for AIDS among adolescents and adults. JAMA. 1993;269(6): 729-730.
5. Garber A. Benefits versus profits - has the Orphan Drug Act gone too far? Pharmacoeconomics. 1994; 5(2):88-92.
6. 21 Code of Federal Regulations (CFR) 316.2.
7. Peabody JW, Ruby A, Cannon P. The economics of orphan drug policy in the US - Can the legislation be improved? Pharmacoeconomics. 1995;8(5):874-884.
8. Arno PS, Bonuck K, Davis M. Rare disease, drug development, and AIDS: the impact of the Orphan Drug Act. Milbank Quarterly. 1995;73(2):231-252.
9. Haffner ME. The United States Orphan Drug Act: Challenges and successes. Drug Inf. J. 1997;31: 23-25.
10. Tufts Center for the Study of Drug Development.
11. Statements by Michael Friedman, Deputy Commissioner for Operations, Food and Drug Administration, Department of Health and Human Services. Before the Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Reform and Oversight, U.S. House of Representatives; Sept 12, 1996.
12. Haffner ME, Kelsey JV. Evaluation of orphan products by the US Food and Drug Administration. Int J Technol Assess Health Care. 1992;8(4):647-657.
13. Orphan Disease Update 1998 XV(3):6.
14. 21 Code of Federal Regulations (CFR) Part 316. Orphan Drug Regulations: Final Rule; Federal Register. December 29, 1992.
15. Spilker B. Orphan Drug Act of 1983. Drug News Perspectives. 1996;9(8):460-462.
16. Myers A. Orphan drugs: The current situation in the United States, Europe, and Asia. Drug Inf J. 1997; 31(1):101-104.
17. 21 Code of Federal Regulations (CFR) 316,316.3(b) (12,13).
18. Chew N, Morgan J, Wantowski C. Taming the paper tiger at FDA. App Clin Trials. 1998;7(2):36-40.
19. Haffner ME. Orphan Drug development - International program and study design issues. Drug Inf J. 1998;32:93-99.
20. Shulman SR, Manocchia M. The US Orphan Drug Programme 1983-1995. Pharmacoeconomics. 1997; 12(3):312-326.
21. Pillar B. Orphan Products: drugs and devices for rare diseases. Nursing Econ. 1993:11(2):99-102.